Epitopes of MUC1 Tandem Repeats in Cancer as Revealed by Antibody Crystallography: Toward Glycopeptide Signature-Guided Therapy
文献类型：期刊论文
| 作者 | Zhou, Dapeng2; Xu, Lan3; Huang, Wei1,4; Tonn, Torsten5,6 |
| 刊名 | MOLECULES
 |
| 出版日期 | 2018-06 |
| 卷号 | 23期号:6 |
| 关键词 | MUC1 tandem repeat antibodies glycopeptide co-crystal |
| ISSN号 | 1420-3049 |
| DOI | 10.3390/molecules23061326 |
| 文献子类 | Review |
| 英文摘要 | Abnormally O-glycosylated MUC1 tandem repeat glycopeptide epitopes expressed by multiple types of cancer have long been attractive targets for therapy in the race against genetic mutations of tumor cells. Glycopeptide signature-guided therapy might be a more promising avenue than mutation signature-guided therapy. Three O-glycosylated peptide motifs, PDTR, GSTA, and GVTS, exist in a tandem repeat HGVTSAPDTRPAPGSTAPPA, containing five O-glycosylation sites. The exact peptide and sugar residues involved in antibody binding are poorly defined. Co-crystal structures of glycopeptides and respective monoclonal antibodies are very few. Here we review 3 groups of monoclonal antibodies: antibodies which only bind to peptide portion, antibodies which only bind to sugar portion, and antibodies which bind to both peptide and sugar portions. The antigenicity of peptide and sugar portions of glyco-MUC1 tandem repeat were analyzed according to available biochemical and structural data, especially the GSTA and GVTS motifs independent from the most studied PDTR. Tn is focused as a peptide-modifying residue in vaccine design, to induce glycopeptide-binding antibodies with cross reactivity to Tn-related tumor glycans, but not glycans of healthy cells. The unique requirement for the designs of antibody in antibody-drug conjugate, bi-specific antibodies, and chimeric antigen receptors are also discussed. |
| WOS关键词 | CHIMERIC ANTIGEN RECEPTOR ; SIALYL-TN-ANTIGENS ; MHC CLASS-I ; ANTI-MUC1 MONOCLONAL-ANTIBODY ; SYNTHETIC ANTITUMOR VACCINES ; HUMAN-IMMUNOGLOBULIN HEAVY ; EPITHELIAL OVARIAN-CANCER ; ADVANCED BREAST-CANCER ; TUMOR-ASSOCIATED MUC1 ; O-GLYCOSYLATION |
| 资助项目 | National Natural Science Foundation of China[81570007] ; National Key Research and Development Plan[2017YFA0505901] |
| WOS研究方向 | Biochemistry & Molecular Biology ; Chemistry |
| 语种 | 英语 |
| WOS记录号 | WOS:000435875400088 |
| 出版者 | MDPI |
| 源URL | [http://119.78.100.183/handle/2S10ELR8/279721]  |
| 专题 | 生物技术药物研发中心（筹） 药物安全性评价中心 |
| 通讯作者 | Zhou, Dapeng; Xu, Lan |
| 作者单位 | 1.ShanghaiTech Univ, IHuman Inst, Shanghai 201203, Peoples R China; 2.Tongji Univ, Sch Med, Shanghai Pulm Hosp, Shanghai 200092, Peoples R China; 3.ShanghaiTech Univ, Lab Antibody Struct, Shanghai Inst Adv Immunochem Studies, Shanghai 201203, Peoples R China; 4.ShanghaiTech Univ, CAS Key Lab Receptor Res, Shanghai Inst Mat Med, Chinese Acad Sci, Shanghai 201203, Peoples R China; 5.German Red Cross Blood Donat Serv North East, Inst Transfus Med Dresden, D-01307 Dresden, Germany; 6.Carl Gustav Carus Tech Univ, Fac Med, D-01307 Dresden, Germany |
| 推荐引用方式 GB/T 7714 | Zhou, Dapeng,Xu, Lan,Huang, Wei,et al. Epitopes of MUC1 Tandem Repeats in Cancer as Revealed by Antibody Crystallography: Toward Glycopeptide Signature-Guided Therapy[J]. MOLECULES,2018,23(6). |
| APA | Zhou, Dapeng,Xu, Lan,Huang, Wei,&Tonn, Torsten.(2018).Epitopes of MUC1 Tandem Repeats in Cancer as Revealed by Antibody Crystallography: Toward Glycopeptide Signature-Guided Therapy.MOLECULES,23(6). |
| MLA | Zhou, Dapeng,et al."Epitopes of MUC1 Tandem Repeats in Cancer as Revealed by Antibody Crystallography: Toward Glycopeptide Signature-Guided Therapy".MOLECULES 23.6(2018). |
入库方式： OAI收割
来源：上海药物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。